Global Digestive Enzymes Market - 2020-2027
発行: DataM Intelligence
世界の消化酵素市場は、胃腸障害の患者増加や、胃腸の健康に関する知識の普及、予防的健康管理に対する関心の増大、そして高齢者人口の増加といった要因に支えられて、今後も拡大傾向が続くと見られています。新型コロナウイルス感染症 (COVID-19) の感染拡大に際しても、消化促進による免疫機能の強化を狙って消化酵素が処方されることが多く、それも市場の成長促進に貢献しています。
当レポートでは、世界の消化酵素の市場について分析し、市場の基本構造および最新情勢、全体的な市場動向の見通し (今後8年間分)、酵素の種類別・原料別・用途別・流通チャネル別および地域別の詳細動向、主な市場促進・抑制要因、市場競争構造、主要企業のプロファイル・事業戦略、新型コロナウイルス感染症 (COVID-19) の影響などについて調査しております。
The global digestive enzymes market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Digestive enzymes are a group of enzymes that break down polymeric macromolecules into their smaller building blocks, in order to facilitate their absorption by the body. Digestive enzymes play a key role in regulating and maintaining the functions of the digestive system properly. These enzymes not only helps in digestion but due to excess or lack of these enzymes, one can face difficulties in digestions too. The market is growing due to the rising geriatric population, the rising prevalence of gastrointestinal disorders, increasing awareness about health, and focus on preventive health management are contributing to the global digestive enzymes market growth.
The global digestive enzymes market growth is driven by the increasing prevalence of gastrointestinal disorders, awareness about the gastrointestinal health, increasing focus to the preventive health management are the factors to the global digestive enzymes market growth in the forecast period.
Increasing geriatric population and the rising prevalence of gastrointestinal disorders
The global population is aging rapidly, owing to reduced birth rates and increasing life expectancy. The demographic trend toward an aging population represents a growing need for the management of disorders, such as GI tract obstructions. According to the report "World Ageing Population, 2019", the older population of age 65 and above accounted for approximately 702.9 million all around the world, and it is expected to reach around 1,548.9 million.
The secretion of digestive enzymes usually decreases with age, which contributes to high levels of gastric discomfort, lower digestion rates, reduced food consumption, and/or a variety of other GI disorders. Therefore, with the increasing geriatric population, the market for digestive enzymes is expected to increase, over the forecast period.
Presence of a large number of small and big companies
Presence of a large number of small and big companies makes the global market for digestive enzymes competitive in nature. Digestive enzyme supplements have to comply with various regulatory bodies including the U.S. Food and Drug Administration, Dietary Supplement Health and Education Act of 1994, and Natural Health Products Regulations for manufacturing and use. In order to grow in such a competitive environment, the established players are investing heavily in research and development to come up with better products. They are also embarking upon partnerships with retail chain companies to improve sales.
Risks associated with use is likely to hinder the market growth
On the contrary, the risks for most enzyme supplements are pretty minimal. Digestive enzymes may trigger a number of side effects, including stomach pain, nausea, diarrhea, and vomiting. In addition, some people may experience allergic reactions to digestive enzymes.
Bromelain, the enzyme from the pineapple, may have anti-platelet activity. If a person take blood thinners or have anti-platelet activity, taking it could possibly increase the risk of bleeding. Pregnant and lactating women are advised to consult their doctor before taking these products.
COVID-19 Impact Analysis
Although COVID-19 primarily a respiratory disease, growing evidence shows that it can affect the digestive system and present with gastrointestinal (GI) symptoms. In patients with COVID-19, the normal intestinal mucosa can be disrupted by the severe acute respiratory syndrome coronavirus virus, and this could result in GI symptoms and a compromise in nutrient absorption. Optimization of oral diet is still recommended. However, given the GI effects of COVID-19, a fraction of infected patients have poor appetite and would not be able to meet their nutrition goals with oral diet alone. For this at-risk group, which includes those who are critically ill, enteral nutrition is the preferred route to promote gut integrity and immune function. In carrying this out, nutrition support practices have been revised in such ways to mitigate viral transmission and adapt to the pandemic. To counter this situation the doctors are prescribing the digestive enzymes to the patients. Thus, the pandemic has incresed the sale and ultimately growth of the digestive enzymes market in the forecast period.
By enzymes type, the digestive enzymes market is classified into carbohydrase, protease, lipase, amylase, maltase, lactase, and other
Amylase segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Amylase is essential for the digestion of carbohydrates. It breaks down starches into sugars. Amylase is secreted by both the salivary glands and the pancreas. The measurement of amylase levels in the blood is sometimes used as an aid in diagnosing various pancreas or other digestive tract diseases. High levels of amylase in the blood may indicate a blocked or injured duct of the pancreas, pancreatic cancer, or acute pancreatitis, a sudden inflammation of the pancreas.
Low levels may indicate chronic pancreatitis (ongoing inflammation of the pancreas) or liver disease.
Amylase health benefits include the ability to fight diabetes. According to a 2013 study published in the Journal of Clinical & Diagnostic Research, type 2 diabetes patients were found to have high blood sugar levels that correlated with low serum amylase levels. The study suggests that amylase plays an important role in maintaining the health of the pancreas. Low amylase levels have been linked to an increased risk of diabetes as well as metabolic syndrome. Amylase health benefits include the ability to reverse diabetes symptoms by reducing high blood sugar levels.
Amylase has the ability to provide the body with a natural source of energy. It helps break down starch so the body can use it as fuel. Amylase plays an important role in breaking down high-starch foods like bread, grains, cereal, rice, pasta, beans, potatoes and corn. Without amylase, the body wouldn't be able to convert these carbohydrates into energy.
By processing starches in diet, amylase aids in the digestive process. It helps the body absorb nutrients form the food while breaking down carbohydrates. Amylase helps keep digestive problems at bay while ensuring that your body absorbs the nutrients from the food we eat
On the basis of origin, the digestive enzymes market is classified into animal, microbial, plant.
The animal origin are expected to dominate the digestive enzymes market during the forecast period
The major factors responsible for the growth of this segment include the efficiency of these animal-derived enzymes in various diseases or conditions, such as pancreatitis, exocrine pancreatic insufficiency, and pancreatic cancer. Hence, the rising prevalence of these diseases may influence market growth. Digestive enzymes from animal origin often come from the pancreatic or stomach enzymes in cows or pigs. Unlike plant-based enzymes, they are only functional at higher pH levels. Therefore, they are less efficient for aiding digestion in the stomach compared to plant-based digestive enzymes. However, specific animal-based enzymes such as pancreatin may be useful for aiding conditions such as pancreatitis, exocrine pancreatic insufficiency, and pancreatic cancer. Pancreatin contains the proteases, amylases, and lipases that a normally functioning pancreas would have; therefore, this enzyme would be useful for targeting an isolated problem in the pancreas.
According to the Cancer Research UK, new cases for pancreatic cancer accounted for almost 10, 257 in the United Kingdom, for 2015-2017. The animal-based enzyme is currently preferred as standard care of treatment for these diseases. The reason behind it may be similar pathophysiology of humans and animals. For instance, the pancreatic pathophysiology of hogs is very much alike to that of humans. However, ethical issues associated with animal origin products in some consumers are expected to hamper the segment's growth.
The microbial enzyme, on the other hand, is expected to witness the fastest growth rate over the forecast period. This growth rate of the microbial origin products can be attributed to factors, such as low production cost and high enzymatic activity. Microbial enzymes are capable of degrading toxic chemical compounds of industrial and domestic wastes (phenolic compounds, nitriles, amines etc.) either via degradation or conversion.
The microbial enzymes have gained recognition globally for their widespread uses in various sectors of industries, e.g., food, agriculture, chemicals, medicine, and energy. Enzyme mediated processes are rapidly gaining interest because of reduced process time, intake of low energy input, cost effective, nontoxic and eco-friendly characteristics. This factor is driving the growth of the segment in the forecast period.
North America region holds the largest market share global digestive enzymes market
North America region is dominating the global digestive enzymes market accounted for the largest market share in 2019, owing to the large investment in healthcare and pressing schedules and unhealthy eating habits of people, primarily in the U.S. is said to be driving the market in the region. The increasing prevalence of chronic gastrointestinal diseases, rapidly aging population, growing demand for preventive medicine, and the presence of major market players are primary factors contributing to the large market size. According to the US Census Bureau, in 2018, the geriatric population in the United States was recorded with approximately 52 million. Furthermore, in 2018, around 14.8 million people were diagnosed with ulcers in the United States, according to the Centers for Disease Control and Prevention
Apart from the high prevalence of GI disorders, the changing lifestyle, unhealthy eating habits, and high disposable income are contributing to the high growth rates. On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period.
The digestive enzymes market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Zeus Biotech Limited, Klaire Labs, Amway Corporation, AbbVie Inc., and Biotics Research Corporation, National Enzyme Company, Country Life LLC., Garden Of Life Inc., Rainbow Light Nutritional Systems Inc., Food State Inc among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the digestive enzymes market globally.
Overview: Klaire Labs is the flagship brand of SFI USA, which is based in Reno Nevada. The SFI group is a global premium natural healthcare company with headquarters in Sydney, Australia. Tribune. For nearly half a century, Klaire Labs has been developing premium, hypoallergenic supplements sold exclusively through healthcare professionals. To formulate and manufacture the purest, most potent nutraceuticals possible, thereby empowering clinicians with consistently reliable performance.
In 2017, three brands become one as sister brands ProThera Inc. and Complementary Prescriptions unify under Klaire Labs.
Product Portfolio: The Company's portfolio comprised of amino acids and proteins, accessory nutrients, hormones, and glandular, antioxidants and cell protectors, enzymes, lipids and essential fatty acids, topical products and others.
The global digestive enzyme market report would provide an access to an approx. 77 market data table, 69 figures and 300 pages.
LIST NOT EXHAUSTIVE